<DOC>
	<DOCNO>NCT02283957</DOCNO>
	<brief_summary>Study 4975-MN-202 double-blind , placebo-controlled , parallel group , single-injection study subject randomize receive three dose CNTX-4975 placebo inject intermetatarsal space around Morton 's neuroma . The injection study medication administer ultrasound-guided needle placement follow ankle block anesthesia . The study staff telephone subject Week 1 postinjection subject return clinic postinjection Weeks 2 , 4 , 8 , 12 study assessment .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety CNTX-4975 Subjects With Painful Intermetatarsal Neuroma ( Morton 's Neuroma )</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Neuroma</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female age &gt; 18 year time Screening Visit . 2 . Pain associate intermetatarsal neuroma ( Morton 's neuroma ) minimum 3 month prior Screening . 3 . Diagnosis Morton 's neuroma , confirm evidence focal tenderness pain distal third intermetatarsal space , AND either Presence neuroma ultrasound , Elicitation Mulder 's sign positive Gauthier 's test . 4 . A mean neuroma foot pain score 4 great 7 day prior dose ( NPRS , 010 ) rat daily bedtime ( 9:00 PM Â± 3 hour ) average pain walking last 24hours . At least 5 7 score week prior dose must record . 5 . Tried conservative treatment analgesic ( acetaminophen nonsteroidal antiinflammatory drug ) nonpharmacologic therapy ( wide shoe , orthotics , and/or arch support ) without complete success . 6 . Female childbearing potential , defined postmenopausal least 1 year , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) , practice one follow medically acceptable method birth control throughout study period : Hormonal method oral , implantable , injectable , transdermal contraceptive minimum 1 full cycle ( base subject 's usual menstrual cycle period ) investigational product ( IP ) administration . Total abstinence sexual intercourse since last menses IP administration . Intrauterine device . Double barrier method ( condom , sponge , diaphragm , spermicidal jelly cream ) . 7 . Willing able understand study requirement , abide study restriction , complete study procedure , pain scale , daily IWRS/IVRS entry , communicate meaningfully study personnel . 8 . Signed Informed Consent Form approve Institutional Review Board . 9 . Subject agrees take rescue medication neuroma foot pain time screen study completion , agree discontinue topical medication neuroma pain Screening . Exclusion criterion : 1 . Clinically significant bursitis either foot . 2 . The subject one painful intermetatarsal neuroma affected foot , opinion Investigator , would interfere evaluation symptom functional limitation arise intermetatarsal neuroma affected foot . 3 . Radiography within 6 month Treatment Visit ( Day 1 ) exclude musculoskeletal pathology must perform , include osseous abnormality stress fracture , osteophyte , tumor , cyst bone toe adjacent third intermetatarsal space significant evidence arthritis joint 3rd 4th metatarsalphalangeal joint interphalangeal joint 3rd 4th toe . 4 . Previous neurectomy nerve . 5 . Any painful condition prior surgery affect ankle foot , , judgment investigator , might adversely impact interpretation study data . 6 . Other painful foot pathology ( e.g. , bunion , hammertoe , plantar fasciitis etc . ) evidence clinically meaningful ischemia , judgment investigator medical monitor , would interfere evaluation symptom functional limitation arise intermetatarsal neuroma . 7 . Other chronic pain anywhere body great equal intensity foot pain intermetatarsal neuroma . 8 . Signs arterial insufficiency foot , include clinically meaningful edema . 9 . Current use opioids condition . 10 . Corticosteroid injection affect foot within 30 day Screening . 11 . History clearly document allergic reaction local anesthetic capsaicin . 12 . Prior use injection sclerosing agent , alcohol phenol , affected foot Morton 's neuroma . 13 . Presence medical condition unstable health status , judgment investigator , might adversely impact conduct study result data , include chronic condition likely alter rate heal likely result safety complication unrelated study medication , uncontrolled diabetes mellitus vascular disease . 14 . Regular use anticoagulant blood thinner ( except lowdose aspirin Plavix allow ) . 15 . Active cutaneous disease anticipate site study drug injection would prevent safe administration study drug . 16 . Ulcer open wound anywhere affected foot . 17 . Clinically significant abnormal laboratory result Screening Visit ( opinion investigator ) . 18 . Has diabetic neuropathy peripheral neuropathy affect foot . 19 . Use investigational medication 30 day prior current study schedule receive agent participate current study . 20 . Prior participation ALGRX4975 CNTX4975 study . 21 . Has history substance use disorder within previous year define Diagnostic Statistical Manual Mental Health Disorders , fifth edition , current evidence substance use disorder , receive medicinal treatment drug abuse , test positive upon urine drug screen substance abuse . 22 . Has positive pregnancy test Screening Treatment Visit . 23 . Has condition take medication would contraindicate study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>